PharmX Technologies (ASX:PHX) ROCE %

: 4.12% (As of Dec. 2023)

View and export this data going back to 1973. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PharmX Technologies's annualized ROCE % for the quarter that ended in Dec. 2023 was 4.12%.

PharmX Technologies ROCE % Historical Data

The historical data trend for PharmX Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmX Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-4.33

4.25

7.73

1.46

-2.67

PharmX Technologies Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															3.13	-0.16	-3.06	-2.29	4.12

PharmX Technologies ROCE % Calculation

PharmX Technologies's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-0.665	/	( ( (30.769 - 5.114)	+	(36.52 - 12.29) )	/ 2 )
	=	-0.665	/	( (25.655	+	24.23)	/ 2 )
	=	-0.665	/	24.9425
	=	-2.67 %

PharmX Technologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	0.872	/	( ( (36.52 - 12.29)	+	(29.596 - 11.527) )	/ 2 )
	=	0.872	/	( ( 24.23	+	18.069 )	/ 2 )
	=	0.872	/	21.1495
	=	4.12 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

PharmX Technologies (ASX:PHX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PharmX Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of PharmX Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmX Technologies (ASX:PHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PharmX Technologies Ltd (ASX:PHX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Castlereagh Street, Level 11, Sydney, NSW, AUS, 2000

Website

https://www.corumgroup.com.au

PharmX Technologies Ltd Formerly Corum Group Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business. the company discontinued the e-commerce business in 2022.